India, Feb. 11 -- Novartis AG (NVS), on Tuesday, announced that it has agreed to acquire privately held, clinical-stage biopharmaceutical company Anthos Therapeutics Inc. for up to $3.1 billion.
As part of the agreement terms, Novartis will make an upfront payment of $925 million upon closing of the transaction, and additional payments totaling up to $2.15 billion based on meeting certain regulatory and sales milestones. The deal is expected to be completed in the first half of 2025.
Anthos was launched by Blackstone Life Sciences and Novartis in 2019. As part of the launch, Novartis had licensed the global rights to develop and commercialize Abelacimab to Anthos in 2019.
With Novartis now acquiring Anthos, Abelacimab is being brought ba...